

2026 ODIN GRANT TYPE 1 ABSTRACT

TIPS & Q+A

June 2026

THE ODIN SECRETARIAT

Contact us at odin@au.dk



Chantelle Dana Driever

Programme Manager



Jerin Lubna

Programme Officer




Anne Mette Fisker Hag

Programme Officer

Reviewers have varied backgrounds

- All reviewers are scientists, but they are not all experts in your exact field, disease area, model, or technology.
- Don't assume they will infer why your project fits ODIN.
- Make it easy for them to understand, assess, and score your project.
- Read 'abstract review framework' first

Tip: Avoid field-specific shorthand unless you explain/define it.



Q3: Unmet Need, Scientific Approach and Openness

- Important: relates to 3 reviewer questions
- 4500* characters (incl. spaces), use them carefully
- Consider using short headings to guide reviewers

Element	Suggested char. length	What reviewers need to understand
Need/gap	700–900	What need are you addressing within ODIN's scope, and why are current approaches insufficient?
Aim, rationale and approach	700–900	What are you trying to achieve, why is the logic credible, and what is the overall project concept?
Methods/technologies and novelty	1400–1600	What will you do, and how does it differ from or improve on current approaches? Detailed state-of-the-art analysis is NOT needed at this stage.
New knowledge, open outputs and sharing	900–1100	What will be generated, what would successful delivery look like, and how will it be shared openly?

Tip: Suggested char. length is not an exact formula. It helps avoid too much background and too little project-specific detail.



Q3: Openness

- **What concrete, precompetitive outputs will be created, and in what open form will they be shared?**
E.g. exploratory dataset, characterised model, proof-of-concept method, benchmarked workflow, documented protocol, preliminary assay, open research tool, etc.
- **How will others access and build on them?**
E.g. open repository, publications, protocol platform, dataset release, software/code sharing, or another appropriate route.

Tip: Name the concrete outputs. Do not rely on generic dissemination language.



Q5: Value creation: what can others do with the outputs?

Q3: What will the project generate and share openly?

Q5: Who can use those outputs, how can they use them, and what could they enable?

- For each key output, explain:
potential user → possible use → broader value/innovation path
- Value can be scientific, technical, methodological, translational, or ecosystem-level — but the **link to future innovation in drug discovery and/or diagnostics should be made obvious.**
- For platforms/tools/methods: explain how the output could eventually apply across other NNF-relevant scope areas.



Q4: Team composition and industry engagement

Make clear:

- **How the disciplines fit together**

What complementary expertise does each partner bring?

Explain how the scientific, technical, clinical, methodological, and/or industry perspectives combine to strengthen the project.

- **Who contributes what**

Roles should be specific enough that reviewers can see there are no major competency gaps.

- **Explain company contribution and why it matters**

Industry partners should not appear decorative, even if their role is mainly advisory.



Q6: Keep the budget realistic and linked to activities

- Include:
 - which partner needs what
 - main cost drivers and how they link to planned activities
 - how costs support expected outputs
- Remember: for-profit companies cannot receive ODIN funding. This will result in admin rejection.

Tip: Do not list budget categories only; explain how the desired resources support the work and expected outputs.



MANDATORY before submission:

Main Applicant **must** contact their local ODIN associate

University of Southern Denmark

- Business Developer, Liv Thomsen litho@sdu.dk

Technical University of Denmark

- Business Developer, Elias Zafirakos eliza@dtu.dk

University of Copenhagen

- Business Developer, Hanne Junker Elmelund hanne.elmelund@adm.ku.dk

Aarhus University

- Kitchen: connect with the business developer dedicated to your department:
<https://kitchen.au.dk/en/til-forskere/raadgivning/department-contacts>

Aalborg University (Funding Specialists)

- Freja Suhr Malmberg, Funding Advisor (Klinisk Inst), fsm@dcm.aau.dk
- Kristian Bering (Institut for Kemi og Biovidenskab), kbe@bio.aau.dk
- Camilla Böhme Kristensen (Institut for Medicin og Sundhedsteknologi), camillabk@hst.aau.dk

FINAL CHECKLIST

- ✓ **Contact the main applicant's BD** to ensure project appears to be precompetitive, does not appear to violate any existing IPR, and foreground knowledge generated can be shared openly.
- ✓ Ensure the main applicant is eligible
- ✓ Submit via main applicant's WL profile
- ✓ At least one company LOS/email with concrete in-kind
- ✓ Ensure minimum team- can add more later
- ✓ Don't list postdoc/PhD in the TEAM section at this stage- only co-applicant leaders (assistant prof up).
- ✓ Postdoc/PhD can be mentioned in BUDGET section
- ✓ Submit by **15:00 on 16 June**


Tip: If something matters for scoring, do not leave it implicit.

Questions?

Keep up to date on ODIN


Sign-up for our newsletter:

<https://projects.au.dk/open-odin/newsletter>



Follow us on LinkedIn:

<https://www.linkedin.com/company/open-odin/>



THANK YOU!

